- BioCentriq, a leading cell therapy CDMO, has entered into a strategic partnership with Orchestra Life Sciences to enhance its $12 million expansion in Princeton, New Jersey.
- The collaboration will optimize BioCentriq’s new 60,000 sq. ft. facility, focusing on advanced manufacturing technologies, regulatory compliance, and digital integration.

BioCentriq has announced a strategic collaboration with Orchestra Life Sciences, aimed at optimizing its $12 million investment in a new cell therapy facility in Princeton, New Jersey. The 60,000 sq. ft. site, expected to be fully operational by Q2 2025, will offer advanced cell therapy development, GMP manufacturing, and testing capabilities, meeting the rigorous standards of US FDA and EU GMP Annex 1 regulations.
This partnership is part of BioCentriq’s broader effort to expand its capabilities in response to the growing demand for cell therapy solutions. The collaboration will involve the implementation of cutting-edge manufacturing technologies and the development of a fully integrated digital ecosystem. Orchestra Life Sciences will contribute its expertise in facility design, automation, and quality management to ensure the facility meets the highest standards of operational excellence.
Syed T. Husain, Chairman and CEO of BioCentriq, commented on the partnership, stating, “This collaboration will enable us to accelerate our capability and bring additional infrastructure and capacity to industry in support of innovative cell therapies.” Orchestra Life Sciences will play a crucial role in optimizing the facility’s design, workflows, and regulatory compliance processes.
The collaboration between BioCentriq and Orchestra Life Sciences will enhance the company’s ability to serve both clinical- and commercial-stage clients in the cell therapy sector. Orchestra Life Sciences brings a wealth of experience in advanced therapy manufacturing, having worked with over 30 life sciences companies to tackle complex manufacturing challenges.
Emilie Pelletier, Co-Founder & CEO of Orchestra Life Sciences, expressed her enthusiasm for the collaboration: “This partnership is a major milestone, ensuring that innovative therapies can move seamlessly from clinical development to commercial delivery, ultimately improving access to life-saving treatments for patients.”
Once completed, BioCentriq’s enhanced Princeton facility will serve as a hub for innovation in cell therapy, providing state-of-the-art capabilities for research, development, and production to support the growing cell and gene therapy market.